Nvidia’s results, Indian tariffs, French markets - what’s moving markets
Gregory Weaver, the Chief Financial Officer of Altimmune, Inc. (NASDAQ:ALT), recently acquired 10,000 shares of the company’s common stock. The purchase, valued at approximately $51,996, was made on March 13, 2025, at a weighted average price of $5.1996 per share. This insider purchase comes as the stock trades near its 52-week low of $5.14, with the company’s market capitalization standing at $400 million. According to InvestingPro data, analysts maintain a bullish outlook with price targets ranging from $12 to $28. The shares were bought in multiple transactions, with prices ranging from $5.1950 to $5.1997. Following this transaction, Weaver holds a total of 10,000 shares in the company. InvestingPro analysis reveals the stock has declined nearly 48% over the past year, with 11 additional key insights available to subscribers through their comprehensive Pro Research Report covering 1,400+ US stocks.
In other recent news, Altimmune reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of -0.33, slightly better than the forecasted -0.34. However, the company faced a significant revenue shortfall, reporting $5 million compared to the anticipated $714 million. Despite this, Altimmune remains optimistic about its future prospects, particularly with its drug pemvidutide. Analysts from Citizens JMP and H.C. Wainwright have maintained positive outlooks on Altimmune stock, with price targets of $25 and $12, respectively, citing the drug’s potential in treating metabolic dysfunction-associated steatohepatitis (MASH) and other conditions. Upcoming Phase 2 trials for pemvidutide, expected to begin in mid-2025, are seen as critical for the company’s growth. Altimmune’s strong cash position, with $132 million in reserves, supports its ongoing and future trials. The company is also preparing for a Virtual R&D Day, which is anticipated to be a significant event for investors. These developments highlight Altimmune’s strategic focus on advancing its pipeline and expanding its market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.